CLINICAL_TRIALS
trial_result
· 2025-11-04
Clinical Trial Update: Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease [Phase 3]
Summary
Phase 3 induction study of oral ozanimod for moderately to severely active Crohn's disease was terminated, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Celgene | Conditions: Crohn Disease | Phase 3 | Status: TERMINATED | Results posted: 2025-11-04